Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,369
Recruiting: 3,967
Ph III recruiting: 537
Growth YoY: +9.4%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,405)

clinicaltrialsPublishedShowing 351–400 of 11,047 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06353997	Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients	recruiting	Phase 2	12	Providence Health & ServicesOTHER	1	Sep 16, 2026	clinicaltrials
NCT06427941	A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	630	BeOne MedicinesINDUSTRY	9	Sep 16, 2026	clinicaltrials